diallylnormorphinium-bromide and Morphine-Dependence

A sensitive taste conditioning test was used to measure the aversive effect of a single intraventricular (i.c.v.) or subcutaneous (s.c) injection of an opioid antagonist that readily crosses the blood brain barrier (naltrexone), and one of two that do not (methylnaltrexone and diallylnormorphinium). This was done in drug-naive rats and in rats implanted 5 days earlier with a pellet containing 75 mg morphine. It was found that the morphine exposure had no significant effect on the dose-response curve of the taste aversion produced by s.c. methylnaltrexone and s.c. diallynormorphinium but reduced the lowest effective dose for the other antagonist treatments from three to more than 100 times. Consideration of the data, together with the pharmacokinetic properties of the drugs and the routes of administration used, supported a conclusion that only those aversions involving central antagonist activity show the potentiation effect of chronic morphine treatment. The findings were also discussed with regard to the location of receptors important for aversions produced by opioid antagonists in naive rats.

Topics: Animals; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Synergism; Infusions, Parenteral; Injections, Subcutaneous; Male; Morphine Dependence; Nalorphine; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Rats; Rats, Inbred Strains; Taste

Topics: Animals; Body Weight; Diarrhea; Female; Humans; Intestines; Morphine Dependence; Nalorphine; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome